

Ana BelÃ©n Custodio Carretero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9601618/publications.pdf>

Version: 2024-02-01

11
papers

182
citations

1307594

7
h-index

1372567

10
g-index

12
all docs

12
docs citations

12
times ranked

425
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic opioid therapy in long-term cancer survivors. Clinical and Translational Oncology, 2017, 19, 236-250.	2.4	48
2	Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab. British Journal of Cancer, 2017, 116, 1526-1535.	6.4	46
3	SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults with solid tumors (2018). Clinical and Translational Oncology, 2019, 21, 75-86.	2.4	21
4	Incidence of venous thromboembolic events in cancer patients receiving immunotherapy: a single-institution experience. Clinical and Translational Oncology, 2021, 23, 1245-1252.	2.4	21
5	Top ten errors of statistical analysis in observational studies for cancer research. Clinical and Translational Oncology, 2018, 20, 954-965.	2.4	17
6	Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMEMON National Cancer Registry. Gastric Cancer, 2018, 21, 96-105.	5.3	16
7	Optimal duration of first-line chemotherapy for advanced gastric cancer: data from the AGAMENON registry. Clinical and Translational Oncology, 2020, 22, 734-750.	2.4	8
8	Key points to optimizing management and research on cancer-associated thrombosis. Clinical and Translational Oncology, 2018, 20, 119-126.	2.4	2
9	Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience. Clinical and Translational Oncology, 2021, 23, 1838-1846.	2.4	1
10	Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clinical and Translational Oncology, 2021, 23, 2046-2056.	2.4	0
11	CP-144â€¦Firstline triplet or doublet chemotherapy for HER2 negative advanced oesophagogastric cancer: an analysis from a community practice registry. , 2017, , .		0